The war against the Covid-19 pandemic is not yet over worldwide. Scientists everywhere are trying to develop a vaccine that protects not only the SARS-CoV-2 virus, but also new, similar viruses that may appear in the future.
Scientists from Washington University School of Medicine say they have developed the experimental Covid-19 vaccine that is much more powerful than the others currently under study.
In trials conducted on rats, the team said that the vaccine triggered an immune response to infection 10 times stronger than those of those who survived Covid-19. Furthermore, it also stimulates a strong memory cell response, in which the body remembers the invading virus to make antibodies faster if infected. The team’s vaccines do not require refrigeration like the vaccines made by other companies, which makes it easier to manufacture and ship globally.
The vaccines, developed by Washington Medical University, can both be more potent than those being studied without needing to be frozen.
Dr. Neil King, assistant professor of biochemistry at the Washington School of Medicine, said: “We hope that the nanoparticle vaccine platform can help fight the pandemic that’s causing a lot of damage to the world. The potency, stability, and production capacity of this vaccine make up the difference.” differentiation between it and many others is under study.
Nanoparticles, whether natural or synthetic, mimic the structural features of viruses because they are often similar in size. This makes it easier for nano molecules to mold according to the size and shape of virus receptors.
The UW Medicine vaccine displays 60 copies of Covid-19’s receptor-binding domain, from which the virus allows it to attach to the body’s receptors to enter cells. The body is then trained to recognize these receptors and build antibodies against them to prevent future infections.
The team tested their new nanoparticle vaccine in mice, showing that the injections produced 10 times more neutralizing antibodies than naturally grown antibodies to infections. . What’s more, this happens even when the vaccine is injected at 5 times lower doses.
Vaccination also leads to a powerful B-cell response, which locks onto the surface of invading pathogens and marks them for destruction by other immune cells. They also form invasive virus memory cells to generate antibodies faster in the event of a future infection, which is crucial in finding a vaccine.
The vaccine does not need to be stored at the same freezing temperatures as those developed by Pfizer Inc and Moderna Inc, so it could allow for a much more favorable global vaccination, the team added. Although it has been tested in animals, further studies in humans in the future are needed.
According to KIRO 7, the vaccine is being licensed to two biotech companies for mass production, and clinical trials are expected to begin later this year. Study author, Dr. David Veesler, assistant professor of biochemistry at UW said.“I am delighted that our studies of the antibody response to Covid-19 have led to the development of this promising vaccine.”
Huong Giang (Source: dailymail)